S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
WARNING TO ALL U.S. INVESTORS (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
WARNING TO ALL U.S. INVESTORS (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
WARNING TO ALL U.S. INVESTORS (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
WARNING TO ALL U.S. INVESTORS (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
BREAKING: Tiny biotech successfully treats blindness (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
BREAKING: Tiny biotech successfully treats blindness (Ad)
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Here’s What Driving the 125% YTD Gains for Upstart Holdings Stock
NASDAQ:SGEN

Seagen (SGEN) Stock Forecast, Price & News

$195.19
-0.19 (-0.10%)
(As of 06/5/2023 ET)
Compare
Today's Range
$194.43
$196.16
50-Day Range
$187.64
$206.25
52-Week Range
$116.08
$207.16
Volume
1.08 million shs
Average Volume
1.56 million shs
Market Capitalization
$36.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$190.47

Seagen MarketRank™ Forecast

Analyst Rating
Hold
2.35 Rating Score
Upside/​Downside
2.4% Downside
$190.47 Price Target
Short Interest
Healthy
3.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.11
Upright™ Environmental Score
News Sentiment
0.82mentions of Seagen in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$30.56 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.96) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

532nd out of 986 stocks

Biological Products, Except Diagnostic Industry

84th out of 165 stocks


SGEN stock logo

About Seagen (NASDAQ:SGEN) Stock

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also engages in the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

SGEN Stock News Headlines

3 Stocks Worth Buying at 52-Week Lows (SGEN)
Here are three stocks that are trading near their 52-week lows and may be primed for a short-term rally for opportunistic investors
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny? (SGEN)
Despite worries about FTC scrutiny, Pfizer remains optimistic about its planned Seagen acquisition, issuing $31 billion in bonds to finance the deal.
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
StockNews.com Initiates Coverage on Seagen (NASDAQ:SGEN)
StockNews.com Begins Coverage on Seagen (NASDAQ:SGEN)
Seagen Inc. (NASDAQ:SGEN) EVP Sells $66,261.14 in Stock
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Analysts Set Seagen Inc. (NASDAQ:SGEN) PT at $194.73
Seagen (SGEN) Rose on Acquisition Announcement
Seagen (NASDAQ:SGEN) Shares Gap Down on Insider Selling
Nasdaq 100 Movers: SGEN, AMD
Seagen Inc.
Seagen (SGEN) Receives a Hold from Berenberg Bank
See More Headlines

SGEN Price History

SGEN Company Calendar

Last Earnings
4/27/2023
Today
6/05/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$190.47
High Stock Price Forecast
$229.00
Low Stock Price Forecast
$129.00
Forecasted Upside/Downside
-2.4%
Consensus Rating
Hold
Rating Score (0-4)
2.35
Research Coverage
17 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-31.00%

Debt

Sales & Book Value

Annual Sales
$1.96 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
138,940,000
Market Cap
$36.60 billion
Optionable
Optionable
Beta
0.53

Social Links


Key Executives

  • David R. Epstein
    Chief Executive Officer & Director
  • Todd E. SimpsonTodd E. Simpson
    Chief Financial Officer
  • Vaughn B. HimesVaughn B. Himes
    Chief Technical Officer
  • Roger D. DanseyRoger D. Dansey
    Chief Medical Officer & President-Research
  • Karin A. Tollefson
    Senior VP & Head-Global Medical Affairs













SGEN Stock - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price forecast for 2023?

17 Wall Street research analysts have issued 1 year target prices for Seagen's stock. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they predict the company's stock price to reach $190.47 in the next twelve months. This suggests that the stock has a possible downside of 2.4%.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How have SGEN shares performed in 2023?

Seagen's stock was trading at $128.51 at the beginning of the year. Since then, SGEN shares have increased by 51.9% and is now trading at $195.19.
View the best growth stocks for 2023 here
.

When is Seagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our SGEN earnings forecast
.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Thursday, April, 27th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.11. The biotechnology company earned $519.70 million during the quarter, compared to analysts' expectations of $516.28 million. Seagen had a negative trailing twelve-month return on equity of 23.00% and a negative net margin of 31.55%. The business's revenue for the quarter was up 21.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.74) earnings per share.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (25.02%), BlackRock Inc. (5.97%), Wellington Management Group LLP (3.64%), State Street Corp (1.79%), Geode Capital Management LLC (1.05%) and Avoro Capital Advisors LLC (0.96%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

How do I buy shares of Seagen?

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $195.19.

How much money does Seagen make?

Seagen (NASDAQ:SGEN) has a market capitalization of $36.60 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.

How many employees does Seagen have?

The company employs 3,256 workers across the globe.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.

This page (NASDAQ:SGEN) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -